Allergan Acquires Rights to Bladder Drug from TARIS BiomedicalBy
LiRIS incorporates proprietary technology developed by TARIS designed to continuously deliver lidocaine over an extended period directly to the bladder of patients with IC/BPS. TARIS Biomedical is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts.
Separately, Allergan has received a request from the US Federal Trade Commission for additional information under the Hart-Scott-Rodino Act in connection with Valeant Pharmaceuticals International, Inc.’s unsolicited acquisition proposal of
Valeant’s most recent effort to acquire Allergan was an unsolicited takeover bid in June 2014 following earlier proposals to acquire Allergan, deals that Allergan has thus far rejected. Pershing Square Capital Management, which owns approximately 9.7% of Allergan and supports the takeover, is seeking to call a special meeting to consider the takeover bid.
Source: Allergan â€‹